Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC

Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He
describes the options available for prophylaxis and how he treats the toxicities that do arise.